China
The iceberg beneath the surface – why China's clinical data is being questioned
In the fall of 2016, the curtain was drawn on one of the biggest scandals in medical history: more than 80 percent of China's clinical study data...
How European companies can succeed in the Chinese deal market
China is becoming an increasingly important player in the...
Summit and Akeso plunge into ambiguous data
The candidate who would beat Keytruda on the fingers meets...
Business was brisk in China during July
In July 2025, activity exploded in China's biotechnology...
From underdog to challenger – China's biotech engine accelerates
China's biotechnology sector has quickly become a global innovation powerhouse,...
Bispecific and Chinese the new black in cancer
Cancer is one of the leading causes of death in...
EU imposes restrictions on Chinese medical technology
European Union member states support a new...
China shows its leadership in drug development
Big pharma has long turned to China...
LIDDS accelerates towards the market through issuance
With the drug delivery technology NanoZolid, Swedish LIDDS addresses the...
Chinese investors invest in Scandinavian life science
China's economy is developing rapidly, which has...
Xbrane advances in the red-hot biosimilar market
On March 25, Xbrane Biopharma will close its rights issue...
Xintela: »Interest in cell therapy is very high in Asia«
With a busy 2018 in the rearview mirror, Xintela has...